ASTRAZENECA PLC (ZEG.DE) Stock Fundamental Analysis
FRA:ZEG - GB0009895292 - Common Stock
138.4 EUR
+0.45 (+0.33%)
Taking everything into account, ZEG scores 5 out of 10 in our fundamental rating. ZEG was compared to 50 industry peers in the Pharmaceuticals industry. While ZEG has a great profitability rating, there are quite some concerns on its financial health. ZEG is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
ZEG had positive earnings in the past year.
In the past year ZEG had a positive cash flow from operations.
ZEG had positive earnings in each of the past 5 years.
Each year in the past 5 years ZEG had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 7.38%, ZEG is in the better half of the industry, outperforming 62.00% of the companies in the same industry.
ZEG has a better Return On Equity (18.55%) than 66.00% of its industry peers.
The Return On Invested Capital of ZEG (14.26%) is better than 78.00% of its industry peers.
ZEG had an Average Return On Invested Capital over the past 3 years of 11.62%. This is below the industry average of 14.78%.
The 3 year average ROIC (11.62%) for ZEG is below the current ROIC(14.26%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.38% | ||
| ROE | 18.55% | ||
| ROIC | 14.26% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
1.3 Margins
ZEG has a Profit Margin of 14.68%. This is in the better half of the industry: ZEG outperforms 64.00% of its industry peers.
ZEG's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 24.39%, ZEG is in the better half of the industry, outperforming 66.00% of the companies in the same industry.
In the last couple of years the Operating Margin of ZEG has grown nicely.
ZEG has a Gross Margin of 82.07%. This is amongst the best in the industry. ZEG outperforms 82.00% of its industry peers.
In the last couple of years the Gross Margin of ZEG has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.39% | ||
| PM (TTM) | 14.68% | ||
| GM | 82.07% |
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ZEG is creating some value.
ZEG has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, ZEG has more shares outstanding
ZEG has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 5.41 indicates that ZEG is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.41, ZEG is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
The Debt to FCF ratio of ZEG is 4.01, which is a neutral value as it means it would take ZEG, 4.01 years of fcf income to pay off all of its debts.
ZEG has a Debt to FCF ratio of 4.01. This is comparable to the rest of the industry: ZEG outperforms 58.00% of its industry peers.
ZEG has a Debt/Equity ratio of 0.63. This is a neutral value indicating ZEG is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.63, ZEG is in line with its industry, outperforming 48.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.63 | ||
| Debt/FCF | 4.01 | ||
| Altman-Z | 5.41 |
ROIC/WACC1.61
WACC8.88%
2.3 Liquidity
A Current Ratio of 0.86 indicates that ZEG may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.86, ZEG is doing worse than 80.00% of the companies in the same industry.
ZEG has a Quick Ratio of 0.86. This is a bad value and indicates that ZEG is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.67, ZEG is doing worse than 80.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.86 | ||
| Quick Ratio | 0.67 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 22.30% over the past year.
Measured over the past years, ZEG shows a quite strong growth in Earnings Per Share. The EPS has been growing by 18.59% on average per year.
The Revenue has grown by 15.00% in the past year. This is quite good.
Measured over the past years, ZEG shows a quite strong growth in Revenue. The Revenue has been growing by 17.27% on average per year.
EPS 1Y (TTM)22.3%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%9.6%
Revenue 1Y (TTM)15%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.74%
3.2 Future
The Earnings Per Share is expected to grow by 12.18% on average over the next years. This is quite good.
ZEG is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.76% yearly.
EPS Next Y13.69%
EPS Next 2Y13.68%
EPS Next 3Y12.68%
EPS Next 5Y12.18%
Revenue Next Year9.37%
Revenue Next 2Y7.8%
Revenue Next 3Y7.28%
Revenue Next 5Y6.76%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 18.31, which indicates a rather expensive current valuation of ZEG.
Compared to the rest of the industry, the Price/Earnings ratio of ZEG is on the same level as its industry peers.
When comparing the Price/Earnings ratio of ZEG to the average of the S&P500 Index (27.43), we can say ZEG is valued slightly cheaper.
A Price/Forward Earnings ratio of 15.24 indicates a correct valuation of ZEG.
ZEG's Price/Forward Earnings ratio is in line with the industry average.
ZEG is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.87, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.31 | ||
| Fwd PE | 15.24 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ZEG is valued a bit more expensive than 64.00% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ZEG is valued a bit more expensive than 60.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 61.27 | ||
| EV/EBITDA | 25.48 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of ZEG may justify a higher PE ratio.
A more expensive valuation may be justified as ZEG's earnings are expected to grow with 12.68% in the coming years.
PEG (NY)1.34
PEG (5Y)0.98
EPS Next 2Y13.68%
EPS Next 3Y12.68%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 2.01%, ZEG has a reasonable but not impressive dividend return.
ZEG's Dividend Yield is comparable with the industry average which is at 3.06.
Compared to an average S&P500 Dividend Yield of 2.45, ZEG has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.01% |
5.2 History
The dividend of ZEG has a limited annual growth rate of 1.40%.
Dividend Growth(5Y)1.4%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
59.51% of the earnings are spent on dividend by ZEG. This is a bit on the high side, but may be sustainable.
The dividend of ZEG is growing, but earnings are growing more, so the dividend growth is sustainable.
DP59.51%
EPS Next 2Y13.68%
EPS Next 3Y12.68%
FRA:ZEG (9/11/2025, 7:00:00 PM)
138.4
+0.45 (+0.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners46.88%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap429.11B
Analysts82.94
Price Target157.04 (13.47%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.01% |
Yearly Dividend2.55
Dividend Growth(5Y)1.4%
DP59.51%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.79%
Min EPS beat(2)-1.74%
Max EPS beat(2)9.32%
EPS beat(4)2
Avg EPS beat(4)1.9%
Min EPS beat(4)-1.74%
Max EPS beat(4)9.32%
EPS beat(8)4
Avg EPS beat(8)1.17%
EPS beat(12)8
Avg EPS beat(12)2.95%
EPS beat(16)11
Avg EPS beat(16)2.52%
Revenue beat(2)0
Avg Revenue beat(2)-2.11%
Min Revenue beat(2)-3.99%
Max Revenue beat(2)-0.24%
Revenue beat(4)2
Avg Revenue beat(4)-0.14%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)2.7%
Revenue beat(8)3
Avg Revenue beat(8)-0.29%
Revenue beat(12)4
Avg Revenue beat(12)-0.55%
Revenue beat(16)7
Avg Revenue beat(16)0.32%
PT rev (1m)0.29%
PT rev (3m)-2.53%
EPS NQ rev (1m)0.78%
EPS NQ rev (3m)-2.77%
EPS NY rev (1m)1.07%
EPS NY rev (3m)1.07%
Revenue NQ rev (1m)0.26%
Revenue NQ rev (3m)2.12%
Revenue NY rev (1m)0.7%
Revenue NY rev (3m)0.92%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.31 | ||
| Fwd PE | 15.24 | ||
| P/S | 8.87 | ||
| P/FCF | 61.27 | ||
| P/OCF | 37.45 | ||
| P/B | 11.21 | ||
| P/tB | N/A | ||
| EV/EBITDA | 25.48 |
EPS(TTM)7.56
EY5.46%
EPS(NY)9.08
Fwd EY6.56%
FCF(TTM)2.26
FCFY1.63%
OCF(TTM)3.7
OCFY2.67%
SpS15.6
BVpS12.34
TBVpS-3.98
PEG (NY)1.34
PEG (5Y)0.98
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.38% | ||
| ROE | 18.55% | ||
| ROCE | 17.47% | ||
| ROIC | 14.26% | ||
| ROICexc | 15.63% | ||
| ROICexgc | 78.69% | ||
| OM | 24.39% | ||
| PM (TTM) | 14.68% | ||
| GM | 82.07% | ||
| FCFM | 14.48% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexcg growth 3Y43.28%
ROICexcg growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score7
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.63 | ||
| Debt/FCF | 4.01 | ||
| Debt/EBITDA | 1.36 | ||
| Cap/Depr | 76.24% | ||
| Cap/Sales | 9.21% | ||
| Interest Coverage | 10.19 | ||
| Cash Conversion | 64.97% | ||
| Profit Quality | 98.66% | ||
| Current Ratio | 0.86 | ||
| Quick Ratio | 0.67 | ||
| Altman-Z | 5.41 |
F-Score7
WACC8.88%
ROIC/WACC1.61
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)22.3%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%9.6%
EPS Next Y13.69%
EPS Next 2Y13.68%
EPS Next 3Y12.68%
EPS Next 5Y12.18%
Revenue 1Y (TTM)15%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.74%
Revenue Next Year9.37%
Revenue Next 2Y7.8%
Revenue Next 3Y7.28%
Revenue Next 5Y6.76%
EBIT growth 1Y37.03%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year34.44%
EBIT Next 3Y17.32%
EBIT Next 5Y12.64%
FCF growth 1Y24.74%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y31.54%
OCF growth 3Y25.76%
OCF growth 5Y31.92%